Brain Tumors Research

Brain Tumor Clinical Trials

The key to finding better treatments for aggressive diseases is the constant collaboration between researchers, clinicians and oncologists — who move therapies swiftly from our on-campus research labs to patients. The quality and frequency of this interaction allows us to get potentially life-extending therapies to our patients quickly.

City of Hope is a hub of innovation and progress when it comes to treating brain tumors. Our research and clinical teams work together to advance therapies that more effectively — and directly — target brain tumors. A groundbreaking case study conducted at City of Hope, and published in the New England Journal of Medicine, found that using CAR T cell therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma. And we are researching immunotherapy as a way of disabling cancer cells and finding unique ways to allow cancer drugs to cross the blood-brain barrier.
 
We are world leaders in the field of neural stem cell therapy, a groundbreaking method of delivering chemotherapy drugs directly to tumor sites within the brain — and were the first in the world to apply this exciting breakthrough therapy to brain cancer.
 
For more information about the brain tumor studies listed below, visit City of Hope's clinical trials website. If you have a newly developed or recurrent brain tumor and are interested in learning about our clinical trials or referring a patient for enrollment, please email [email protected].

Recurrent High-Grade Gliomas

NCT05139056: Patients with recurrent high-grade gliomas will soon have the opportunity to participate in a study to assess the safety and effectiveness of multiple doses of neural stem cells in combination with an oncolytic virus.

Principal Investigator: Jana Portnow, M.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

_______________________

NCT04214392: We're recruiting for a study on the possible benefits and optimal doses of CAR T cells with a chlorotoxin tumor-targeting domain to treat MMP2+ recurrent high-grade gliomas.

Principal Investigator: Behnam Badie, M.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

_______________________

NCT04003649: We're recruiting patients for a study that combines two types of immunotherapy using CAR T cells together with nivolumab and/or ipilimumab.

Principal Investigator: Behnam Badie, M.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with recurrent high-grade glioma

_______________________

NCT04661384: Patients with leptomeningeal disease may be eligible to participate in a study of CAR T cell therapy to assess the benefits of treatment using brain tumor-specific immune cells.

Principal Investigator: Lisa Feldman, M.D., Ph.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with leptomeningeal metastases from glioblastoma, ependymoma or medulloblastoma

Learn more about this promising study

_______________________

NCT04510051: Children or young adults with recurrent malignant primary brain tumors can participate in a study to assess the safety and best dose of CAR T cell therapy.

Principal Investigator: Leo Wang, M.D, Ph.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 4 to 25 years old
  • Recurrent malignant primary brain tumors

Brain Metastases

NCT03696030: We're recruiting for a study to evaluate the possible benefits of CAR T cells in patients with recurrent HER2+ brain and/or leptomeningeal metastases.

Principal Investigator: Jana Portnow, M.D.
 
Checklist icon

Patient Enrollment Qualifications

  • Age 18 years or older
  • Diagnosed with HER2+ brain and/or leptomeningeal metastases